Founded in 2015, BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. They are based in Palo Alto, California.
| Website | http://www.bridgebio.com |
| Ticker | BBIO |
| Revenue | $219.1 million |
| Funding | $1.7 billion |
| Employees | 1 (1 on RocketReach) |
| Address | 421 Kipling St, Palo Alto, California 94301, US |
| Phone | +1 650-391-9740 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+97 more
(view full list)
|
| Industry | Pharmaceuticals, Healthcare |
| Competitors | Sanofi, Novo Nordisk, Genentech, Amgen, Takeda, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, Biogen, Lilly India +47 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 54 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular BridgeBio Pharma employee's phone or email?
The BridgeBio Pharma annual revenue was $219.1 million in 2026.
Peter Ressler is the VP of BridgeBio Pharma.
1 people are employed at BridgeBio Pharma.
BridgeBio Pharma is based in Palo Alto, California.
The NAICS codes for BridgeBio Pharma are [32541, 54, 32, 541, 3254, 325].
The SIC codes for BridgeBio Pharma are [873, 87].